We’re looking for financial gurus & article writers to write about trending market news and investment ideas about the stock market. The first tranche of EUR 1 million will be advanced concurrent with the execution of the binding term sheet and the second tranche of EUR 1 million upon the successful conclusion of Relief’s phase 2b/3 clinical trial of intravenous RLF-100TM in the treatment of critical COVID-19 patients with respiratory failure. The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks. document.getElementById('cloake7685b8770c456e1473f5978e5778bdc').innerHTML = ''; In August 2019, divestment of Relief Therapeutics SA to Sonnet BioTherapeutics Inc., an oncology-focused biotechnology company, has been agreed upon and became effective in March 2020. As…. Relief Therapeutics’ RLF-100 has been in the market for over 20 years with a history of safe use in humans in multiple human trials for sarcoidosis, … Relief Therapeutics & and NeuroRx has recently submitted their application for … The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020. RLF-100/Aviptadil is currently tackling ARDS in COVID-19 patients. CONTACT:RELIEF THERAPEUTICS Holding AGRaghuram (Ram) Selvaraju, Ph.D., MBAChairman of the Board Mail: This email address is being protected from spambots. Based on how the sales of the drug goes this could propel an acquisition by NeuroRx to remove the limits on the partnership agreement. Sep 28, 2020 • • 1 minute read. Furthermore, we plan to re-start a clinical development program for RLF-100TM in pulmonary Sarcoidosis later this year.". The two companies have now taken steps to increase manufacturing of the aviptadil drug substance and are in the final stages of contracting with a fill/finish manufacturer, along with a national distribution partner. : +49 (0) 211-529-252-14 Mail: This email address is being protected from spambots. The companies continue to anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 … I predict in the future that NeuroRx may acquire Relief Therapeutics since both companies are already integrated with research and development. Regeneron (REGN) and Relief Therapeutics (OTC:RLFTF) can quickly reduce COVID-19. var path = 'hr' + 'ef' + '='; You’ve been successfully subscribed to our newsletter! You need JavaScript enabled to view it. Summary Relief Therapeutics has a found a new use for Vasoactive Intestinal Peptide by repackaging it as RLF-100 (Aviptadil) to now fight COVID. By January 2021, Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100. You need JavaScript enabled to view it. "We look forward to initiating the development of inhaled RLF-100™ in Europe within the coming months for COVID-19 patients using inhaled Aviptadil. Principals, affiliates, staff or authors of Money Midnight may own positions in the securities listed on the site and that we reserve the right to buy or sell without notice at any time. NeuroRx’s up listing is highly beneficial to both companies. Under the terms of the transaction, Big Rock and NeuroRx will merge and the company is expected to continue to trade on the Nasdaq Stock Market under the symbol “NRXP.” The transaction is expected to occur in the first or second quarter of 2021. You should not base investment decisions solely on this document. The closing of the transaction is subject to customary closing conditions as well as legal and securities regulatory approvals and is expected to occur in Q2 2021. RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. Dr. Jonathan Javitt did not accept his nomination, as announced at the 2020 Ordinary General Meeting, to join the Relief Board of Directors. GENEVA — RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” announces that New York University Langone (NYU Langone Health) is participating in the Phase 2 clinical study of its drug Aviptadil for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19.The multicenter trial will enroll patients … Unfortunately, that means its free cash flow fell significantly short of its reported profits. Its lead drug candidate RLF-100TM (Aviptadil), synthetic vasoactive intestinal peptide (VIP), is being developed in collaboration with NeuroRx, Inc. and is currently being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure 07 December 2020 Correction: NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 … Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH ("AdVita"), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases, today announced the companies have signed a binding term sheet for Relief to acquire all shares of AdVita in exchange for EUR 25 million of Relief common shares, plus possible future contingent milestone payments of up to EUR 20 million. On April 1, 2020, Share Exchange Agreement concluded related to the sale of Relief Therapeutics SA between Sonnet Holdings and the Company. All content here is solely for informational and educational purposes only. Remember that this is for educational purposes only and since our research can be highly speculative, you should not base your decision solely on this document. addyd15ff14d23b491175408c179e001a7b6 = addyd15ff14d23b491175408c179e001a7b6 + 'mc-services' + '.' + 'eu'; RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. You need JavaScript enabled to view it. ABOUT ADVITA LIFESCIENCE GMBH AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and … The trademark filed on Sept 14 could indicate their inhalant based version of the drug in partnership with NeuroRX. Amongst the AdVita assets being acquired in this transaction, Relief will gain further pending intellectual property rights that may cover RLF-100TM inhaled formulation specifications and the potential application of inhaled Aviptadil in the treatment of Acute Respiratory Distress Syndrome (ARDS) and Checkpoint Inhibitor-induced Pneumonitis (CIP). Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel, 85/15 (in favor of Relief) in Europe, and 80/20 (in favor of Relief) in all other territories. It continues to rise up the charts and emerge. Our daily stock market updates, stock market Aviptadil (Vasoactive Intestinal Peptide, VIP), the second product in development, is an abundant biologically active endogenous … Money Midnight is currently seeking to expand our team of contributors. According to the interview with Dr. Javitt the term sheet has already been signed, big banks are already doing their due … "AdVita's intellectual property around inhaled formulations of Aviptadil and its team’s expertise with Aviptadil will be invaluable as we move forward with the development of the inhaled formulation of RLF-100™ for the treatment of COVID-19-related ARDS, as well as other potential lung disease indications, such as pulmonary Sarcoidosis and Chronic Beryllium Disease," said Jack Weinstein, CFO and Treasurer of Relief. Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research. Since July 2020, severe COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. Most recent PR from PR Newswire on 10/07/2020: RELIEF THERAPEUTICS Holding AG (OTCQB: RLFTF) and NeuroRx, Inc. have established supply chain agreements and ordered sufficient drug substance (RLF-100TM) to prepare to treat 1 million patients with COVID-19, should the … Relief Reports Half-Year 2020 Results. In this administratively-controlled clinical trial, intravenous aviptadil, administered as 3 successive 12 hour infusions of 50/100/150 pmol/kg/hr resulted in a 9-fold advantage in both You should note that our authors are not investment advisors. Over the course of the past week, RLFTF as gained as much as 25%, and on Monday the company made a major announcement with regards to its partnership agreement with NeuroRx Inc. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. You can trust the integrity of our balanced, independent financial research. Under the terms of the agreement, Relief will advance a EUR 2 million convertible secured loan to AdVita. Nothing herein should be considered personalized investment advice. NIO Stock: Eaton Vance’s Hexavest buys in, selling Apple and Microsoft, Hexavest, a firm owned 49% by Eaton Vance (EV) has…, On Friday of last week, Novan just hit a new…, Green Energy stocks to watch for this week as Biden takes office, Green energy stocks are going to boom in 2021. Money Midnight, our affiliates or the author may or may not have a position in the securities mentioned and reserves the right to buy or sell at any time without notice. Shares of Relief Therapeutics rose 6.15% today and will continue to do so in the coming months ahead. Our main purpose is to bring traffic to our website. Relief Therapeutics (OTC: RLFTF) is the talk of the town on Wall Street. Sonnet Holdings paid to the Company shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock. Completion of the transaction is subject to approval by stockholders of NeuroRx and Big Rock and other customary closing conditions. 2021-01-21 01:21 ET - News Release. The company is developing a drug candidate RLF-100 for Respiratory Failure in COVID-19 coronavirus patients. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM. Geneva, Switzerland, September 15, 2020 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company"), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced its results for the half year ended June 30, 2020. AdVita Lifescience GmbH was founded in 2019 with the purpose of developing effective products and strategies to improve the therapy and diagnosis of rare lung diseases. NeuroRx a company who is partnered with promising COVID-19 therapeutic maker Relief Therapeutics (OTC: RLFTF) has decided to merge and list with a NYSE company (3-6 months). Relief Therapeutics Stock - Relief Therapeutics Holding Ag Rlftf Stock Chart Technical Analysis For 11 03 2020 Youtube - Rlftf) is the talk of the town on wall street.. Shares of sarepta therapeutics (nasdaq:srpt) were crashing 50.7% as of 11:11 a.m. Ryvu therapeutics is a clinical stage biopharmaceutical company … RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. 1 source for smarter, safer, more profitable investing. Geneva, Switzerland, September 15, 2020 - RELIEF THERAPEUTICS HoldingSA (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company "), a biopharmaceutical company with its lead compound RLF-100 (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced its results for the half year ended June 30, 2020.. Operative Highlights Year to Date 2020: and cryptocurrency investing advice and ideas. On 1 April 2020, Relief divested its subsidiary Relief Therapeutics SA, the focus of which was to develop atexakin alfa, to Sonnet BioTherapeutics, Inc. (“Sonnet Holdings”) through a Share Exchange Agreement (“SEA”) which was executed on 12 August 2019. Relief Therapeutics (OTCQB:RLFTF) has been on a tear. Why RLF-100 is bigger than Pfizer and Moderna’s vaccine. RLF-100TM is believed to be the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung. document.getElementById('cloakd15ff14d23b491175408c179e001a7b6').innerHTML = ''; var prefix = 'ma' + 'il' + 'to'; Dorian Bevec, Ph.D., CSO of AdVita, commented: "We are excited to combine our specific expertise in inhaled formulations of Aviptadil with Relief's comprehensive scientific catalog of the compound and its uses in respiratory diseases.". The Boards of Directors of both NeuroRx and Big Rock have unanimously approved the proposed transaction. Relief Therapeutics (OTC: RLFTF) files SamiAir trademark. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Article content. In addition, subject to certain conditions, a $100 million cash earnout may be payable to NeuroRx pre-merger equity holders if, prior to December 31, 2022, either (1) FDA approval of the Company’s COVID-19 Drug is obtained and the Company’s COVID-19 Drug is listed in the FDA’s “Orange Book” or (2) FDA approval of the Company’s Antidepressant Drug Regimen is obtained and the Company’s Antidepressant Drug Regimen is listed in the FDA’s “Orange Book”. The members of the Relief Board of Directors are Raghuram (Ram) Selvaraju (Chairman), Thomaz Burckhardt and Tom Plitz. No. GENEVA, SWITZERLAND / ACCESSWIRE / January 21, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a … Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Relief Therapeutics (OTC:RLFTF) partner NeuroRx (NRXP) is uplisting to the NASDAQ through a SPAC merger with Big Rock Partners Acquisition (BRPA). Top-line data from this trial are expected at the end of January or early February of this year. We use cookies to ensure that we give you the best experience on our website. In the last twelve months it actually had negative free cash flow, with an outflow of CHF3.5m despite its profit of CHF1.35m, mentioned above. NeuroRx shall prosecute such trademarks in the U.S., Canada and Israel, while Relief shall prosecute trademarks in all other territories. Is Relief Therapeutics (OTC: RLFTF) a good investment? RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. addye7685b8770c456e1473f5978e5778bdc = addye7685b8770c456e1473f5978e5778bdc + 'relieftherapeutics' + '.' + 'com'; ZURICH — Relief Therapeutics said on Monday it is getting more money from its largest stockholder to lift its cash to 48 million Swiss francs ($52 million) to fund trials of a decades-old medicine it hopes to repurpose against COVID-19. var addy_texte7685b8770c456e1473f5978e5778bdc = 'contact' + '@' + 'relieftherapeutics' + '.' + 'com';document.getElementById('cloake7685b8770c456e1473f5978e5778bdc').innerHTML += ''+addy_texte7685b8770c456e1473f5978e5778bdc+'<\/a>'; FOR MEDIA/INVESTOR INQUIRIES: MC Services AGAnne Hennecke / Brittney SojevaTel. By January 2021, Relief and NeuroRx expect to have manufacturing, distribution and logistics capacity in place to deliver sufficient drug quantities to treat 150,000 patients per month with RLF-100. As a public Nasdaq-listed company, NeuroRx expects to have increased access to capital to continue development of its innovative drug pipeline targeting Central Nervous System (CNS)/Psychiatry and Respiratory Disease. Relief Therapeutics Holding has an accrual ratio of 0.20 for the year to June 2020. RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. Subject to certain conditions, an aggregate of 25 million additional shares of Big Rock common stock will be issued to NeuroRx pre-merger equity holders if, prior to December 31, 2022, (1) RLF-100 receives emergency use authorization by the FDA and (2) the FDA accepts the Company’s filing of its application to approve RLF-100. var addyd15ff14d23b491175408c179e001a7b6 = 'relief' + '@'; var prefix = 'ma' + 'il' + 'to'; var addy_textd15ff14d23b491175408c179e001a7b6 = 'relief' + '@' + 'mc-services' + '.' + 'eu';document.getElementById('cloakd15ff14d23b491175408c179e001a7b6').innerHTML += ''+addy_textd15ff14d23b491175408c179e001a7b6+'<\/a>'; Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. As part of their agreement, Relief and NeuroRx intend to pursue the issuance of trademarks on RLF-100. EQS-News: Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large December 18, 2020, 1:00 AM EST